Immunoreceptor Engineering and Synthetic Cytokine Signaling for Therapeutics. Issue 3 (March 2019)
- Record Type:
- Journal Article
- Title:
- Immunoreceptor Engineering and Synthetic Cytokine Signaling for Therapeutics. Issue 3 (March 2019)
- Main Title:
- Immunoreceptor Engineering and Synthetic Cytokine Signaling for Therapeutics
- Authors:
- Scheller, Jürgen
Engelowski, Erika
Moll, Jens M.
Floss, Doreen M. - Abstract:
- Abstract : Cytokines control immune-related events and are critically involved in a plethora of physiological and pathophysiological processes including autoimmunity and cancer development. Accordingly, modulation of natural cytokine signaling by antibodies and small molecules has improved therapeutic regimens. Synthetic biology sets out to optimize immunotherapeutics, with chimeric antigen receptor (CAR) T cell immmunotherapy being the first example to combine synthetic biology with genetic engineering during therapy. Hence, synthetic cytokines and cytokine receptors, as well as constitutively active cytokine receptor variants, are emerging as tools to improve or modulate immunotherapeutic strategies. This review focuses on recent developments in the growing field of synthetic cytokine signaling, providing an outlook for developing applications that involve physiological targets of immunotherapy. Highlights: Synthetic cytokine biology deconstructs and reassembles cytokines and their receptors to design biological devices as therapeutics. Synthetic cytokines, including neoleukins and synthekines, can activate selective or nonnatural receptor combinations and subsequently induce unique signaling patterns. Cytokines coupled to nanoparticles, peptides, or antibodies and fusokines can allow cell-targeted therapies. Naturally occurring and synthetic constitutively active cytokine receptors have been described for all cytokine receptor classes and might improve immunotherapyAbstract : Cytokines control immune-related events and are critically involved in a plethora of physiological and pathophysiological processes including autoimmunity and cancer development. Accordingly, modulation of natural cytokine signaling by antibodies and small molecules has improved therapeutic regimens. Synthetic biology sets out to optimize immunotherapeutics, with chimeric antigen receptor (CAR) T cell immmunotherapy being the first example to combine synthetic biology with genetic engineering during therapy. Hence, synthetic cytokines and cytokine receptors, as well as constitutively active cytokine receptor variants, are emerging as tools to improve or modulate immunotherapeutic strategies. This review focuses on recent developments in the growing field of synthetic cytokine signaling, providing an outlook for developing applications that involve physiological targets of immunotherapy. Highlights: Synthetic cytokine biology deconstructs and reassembles cytokines and their receptors to design biological devices as therapeutics. Synthetic cytokines, including neoleukins and synthekines, can activate selective or nonnatural receptor combinations and subsequently induce unique signaling patterns. Cytokines coupled to nanoparticles, peptides, or antibodies and fusokines can allow cell-targeted therapies. Naturally occurring and synthetic constitutively active cytokine receptors have been described for all cytokine receptor classes and might improve immunotherapy approaches. Fully synthetic cytokine signaling systems can allow precisely orchestrated cellular responses. They have been shown to modulate immune responses and presumably, might support immunotherapeutics. … (more)
- Is Part Of:
- Trends in immunology. Volume 40:Issue 3(2019)
- Journal:
- Trends in immunology
- Issue:
- Volume 40:Issue 3(2019)
- Issue Display:
- Volume 40, Issue 3 (2019)
- Year:
- 2019
- Volume:
- 40
- Issue:
- 3
- Issue Sort Value:
- 2019-0040-0003-0000
- Page Start:
- 258
- Page End:
- 272
- Publication Date:
- 2019-03
- Subjects:
- CAR -- Cytokine receptor -- Cytokine -- Interleukin -- Immunotherapy
Immunology -- Periodicals
571.96 - Journal URLs:
- http://www.sciencedirect.com/science/journal/14714906 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.it.2019.01.001 ↗
- Languages:
- English
- ISSNs:
- 1471-4906
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 9049.630500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 9563.xml